Trial Profile
Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2017
Price :
$35
*
At a glance
- Drugs Vaccinia immune globulin (Primary)
- Indications Eye disorders
- Focus Therapeutic Use
- 02 Feb 2017 New trial record